EUVIMEDEUVIMED entdecken
Open Access

Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy

Thiago P Furtado iD, Eduardo P Miranda iD, Serkan Deveci, Lawrence Jenkins, Joseph Narus, Christian Nelson iD, John P Mulhall

The Journal of Sexual Medicine · 2023

DOI: 10.1093/jsxmed/qdad144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2023. Verfasst von Thiago P Furtado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10022, United …. Hauptthemen laut MEDLINE: Erectile Dysfunction, Priapism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phosphodiesterase type 5 (PDE5) inhibitor labeling states that these agents should not be used in conjunction with other erectogenic medications for fear of priapism occurring.

Aim

We explored the risk of priapism and prolonged erections in men in our post–radical prostatectomy (RP) penile injection program who were using regular PDE5 inhibitor and intracavernosal injections (ICIs) as part of their rehabilitation program.

Methods

The study cohort included men on penile injection therapy who (1) were taking tadalafil 5 mg daily or taking sildenafil 25 mg on noninjection days, (2) had an RP, (3) were using their respective PDE5 inhibitor regularly at the time of penile injection training, and (4) complied with the program instructions regarding penile injection use. Demographics, comorbidity details, PDE5 inhibitor dose and utilization, and injection dose and utilization data were collected. All patients underwent in-office injection training and used trimix (papaverine/phentolamine/prostaglandin E1) as the intracavernosal medication. Outcomes Priapism was defined as a patient self-reported penetration hardness erection ≥4 hours in duration, while prolonged erection was defined as a penetration hardness erection lasting ≥2 hours.

Results

A total of 112 tadalafil users and 364 sildenafil users were compared. Mean age and duration post-RP were 62 ± 14 years and 5.2 ± 12 months, respectively, and there was no difference between tadalafil and sildenafil groups. The mean trimix dose was tadalafil 24 ± 24 units and sildenafil 31 ± 37 units (P < .05). Priapism occurred in 2 (1.7%) of 112 tadalafil users and 5 (1.4%) of 364 sildenafil users (P = .47). Excluding those men experiencing priapism on any occasion, those with any reported penetration hardness erection lasting ≥2 hours were 7 (6.3%) of 112 tadalafil users and 12 (3.3%) of 364 sildenafil users (P < .01). A total of 53% of these prolonged erections occurred within the first 6 injections at home (no difference between tadalafil and sildenafil groups). Clinical Implications We emphasize the need for continued monitoring and education on proper injection techniques to minimize the risk of adverse events in ICI and PDE5 inhibitor combination therapy. Strengths & Limitations This study has a relatively large patient population with a considerable follow-up time. Additionally, the rigorous training, education, and monitoring of the participants, as well as the use of formal definitions for priapism and prolonged erections, enhances the accuracy and reliability of the results. However, there are some limitations, such as social desirability, confounding factors, and recall bias.

Conclusion

There is no significant difference in the incidence of priapism in an ICI program in which men combine ICI with tadalafil or sildenafil. However, tadalafil patients had a higher rate of prolonged erections, which was found to occur mostly early during the titration phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erectile DysfunctionPriapismMaleHumansMiddle AgedAgedPhosphodiesterase 5 InhibitorsSildenafil CitrateTadalafilReproducibility of ResultsPiperazinesPurinesPenile ErectionProstatectomyHeliumNitrogenOxygen

Stichwörter der Autor:innen

PDE5 inhibitorserectile dysfunctionintracavernosal injectionpenile rehabilitationradical prostatectomysildenafiltadalafil

Substanzen

Phosphodiesterase 5 InhibitorsSildenafil CitrateTadalafilPiperazinesPurinestrimixHeliumNitrogenOxygen

Autor:innen und Institutionen

  • Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10022, United States.
  • Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10017, United States.

ORCID-Profile: Thiago P Furtado, Eduardo P Miranda, Christian Nelson

Förderung

  • NCI NIH HHS

Zitieren

APA

Furtado, T. P., Miranda, E. P., Deveci, S., Jenkins, L., Narus, J., Nelson, C., & Mulhall, J. P. (2023). Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdad144

Vancouver

Furtado TP, Miranda EP, Deveci S, Jenkins L, Narus J, Nelson C, et al. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. The Journal of Sexual Medicine. 2023. doi:10.1093/jsxmed/qdad144

BibTeX
@article{Furtado2023,
  author = {Furtado, Thiago P and Miranda, Eduardo P and Deveci, Serkan and Jenkins, Lawrence and Narus, Joseph and Nelson, Christian and Mulhall, John P},
  title = {Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy},
  journal = {The Journal of Sexual Medicine},
  year = {2023},
  doi = {10.1093/jsxmed/qdad144}
}
Kostenlos starten →